Unicycive Therapeutics Reports Clinical Trial Breakthrough
Company Announcements

Unicycive Therapeutics Reports Clinical Trial Breakthrough

Unicycive Therapeutics (UNCY) has shared an update.

Unicycive Therapeutics, Inc. has announced significant success in their Oxylanthanum Carbonate (OLC) UNI-OLC-201 clinical trial, meeting both primary and secondary endpoints. This breakthrough was shared in a press release and during a corporate presentation, signaling potentially positive impacts for the company’s future and stirring interest among investors and market watchers.

See more data about UNCY stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyUnicycive Therapeutics price target raised to $4 from $2.50 at H.C. Wainwright
TheFlyUnicycive Therapeutics files $100M mixed securities shelf
TheFlyUnicycive Therapeutics reports Q3 EPS (13c), consensus (15c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App